Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON APPOINTMENT OF SENIOR MANAGEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* Announcement on Appointment of Senior Management" published by Shanghai Junshi Biosciences Co., Ltd. on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Junshi Biosciences Co., Ltd.*

Mr. Xiong Jun

Chairman

Shanghai, the PRC, 28 August 2020

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Chen Xinjun, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Roy Steven Herbst as independent non-executive Directors.

• For identification purpose only

Stock code: 688180

Stock short name: Junshi Bio

Announcement No.: Lin 2020-010

Shanghai Junshi Biosciences Co., Ltd.* Announcement on Appointment of Senior Management

The Board of Directors of the Company and all Directors warrant that there is no false and misleading statement or material omission herein, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

The "Resolution on Appointment of Senior Management" was considered and approved at the twenty-sixth meeting of the second session of the Board of Directors of Shanghai Junshi Biosciences Co., Ltd. (the "Company") held on 28 August 2020. Details are as follows:

1. Appointment of senior management

In order to fulfill the needs of development of the Company, as nominated by the general manager and approved by the nomination committee of the Board of Directors of the Company in accordance with the Articles of Association, Terms of Reference of the Nomination Committee and the provisions of relevant laws, regulations and policies, the Board of Directors of the Company agreed to appoint Mr. Yin Kan, Mr. Xie Wan and Mr. Ma Jun as the deputy general managers of the Company, effective from the date on which their appointment was approved by the Board of Directors until the expiry of the second session of the Board. Please refer to the attachment of this announcement for details of the biographies of Mr. Yin Kan, Mr. Xie Wan and Mr. Ma Jun.

Mr. Yin Kan, Mr. Xie Wan and Mr. Ma Jun possess the working experience and expertise required for performing duties as deputy general manager. They are capable of serving at the relevant position, and fulfill the qualification for relevant position

under the Company Law of People's Republic of China, the Rules Governing the Listing of Securities on the STAR Market of Shanghai Stock Exchange and the Articles of Association. The Company is not aware of any circumstances under which their appointment will be prohibited pursuant to relevant laws and regulations, and none of them is subject to effective market ban imposed by China Securities Regulatory Commission.

Independent non-executive directors of the Company have expressed their independent opinion of consent on the above matters, and agreed to appoint Mr. Yin Kan, Mr. Xie Wan and Mr. Ma Jun as deputy general manager of the Company.

1. Attachment to online announcement

Independent Opinion of Independent Directors on Relevant Matters of the Twenty-sixth Meeting of the Second Session of the Board of Directors of Shanghai Junshi Biosciences Co., Ltd.

Notice is hereby given.

Shanghai Junshi Biosciences Co., Ltd.

Board of Directors

29 August 2020

Attachment: Biography

Yin Kan, male, was born in June 1964. In 1984, he graduated from Nanjing Pharmaceutical College (currently China Pharmaceutical University) majoring in medicinal chemistry, and obtained a bachelor's degree in science. In 2005, he graduated from Nanjing University and obtained an EMBA degree. His major work experience included: from August 1984 to June 1993, he worked in Changzhou Pharmaceutical Administration Bureau; from June 1993 to July 1994, he served as the head of technology improvement department of Changzhou No. 4 Pharmaceutical Factory; from July 1994 to September 1997, he served as the director of Changzhou No. 3 Pharmaceutical Factory; from September 1997 to November 2002, he served as the deputy general manager at Suzhou Dawnrays Pharmaceutical Co., Ltd.; from November 2002 to September 2003, he was the deputy general manager at Hainan Simcere Pharmaceutical Co., Ltd.; from September 2003 to April 2005, he was the executive deputy general manager at Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.; from May 2005 to November 2005, he served as the executive vice head of science and industry department of China Huayuan Life Industry Co., Ltd.; from November 2005 to October 2009, he was the executive general manager at Guangdong Bangmin Pharmaceutical Co., Ltd.; from October 2009 to February 2012, he was the general manager of the industry business department of Nanjing Pharmaceutical Co., Ltd., the executive director and general manager of Nanjing Tongrentang Pharmaceutical Co., Ltd., as well as the chairman and general manager of Nanjing Tongle Pharmaceutical Co., Ltd.; from February 2012 to July 2016, he served as the general manager of Changzhou Lanling Pharmaceutical Co., Ltd.

Xie Wan, male, was born in March 1973. In 1995, he graduated from Shenyang Pharmaceutical University majoring in micro-biological pharmacy, and obtained a bachelor's degree in engineering. His major work experience included: from July 1995 to November 2010, he was successively the head of production department, the production director, the crafts manager and the operating director of Tianjin Hualida Biological Engineering Co., Ltd.; from November 2010 to April 2016, he was

successively the production director and general manager of production department of Shanghai CP Guojian Pharmaceutical Co., Ltd.

Ma Jun, male, was born in April 1964. In 1985, he graduated from an associated school of Tongji University majoring in heating, ventilation and air conditioning, and obtained a bachelor's degree. In 2009, he graduated from Cheung Kong Graduate School of Business and obtained an EMBA degree. He is currently a doctorate student at Antai College of Economics & Management, Shanghai Jiao Tong University, majoring in MBA. His major work experience included: from June 1985 to June 1993, he was an engineer at Shanghai Pharmaceutical Design Institution of National Medical Products Administration; from June 1993 to April 1994, he served as the engineering manager of engineering department of Shanghai branch of Shenzhen Development Bank Property Corporation; from September 1997 to October 2000, he worked at the Shanghai office of Bechtel Corporation, an American company; from November 2000 to March 2001, he worked at Liandeli Enginering Consultation (Shanghai) Corporation; from April 2001 to April 2005, he served as the general manager at AUSTAR Rui'er Engineering Consultation (Shanghai) Co., Ltd.; from April 2005 to May 2009, he was the general manager of engineering business department of AUSTAR Group; from May 2009 to October 2010, he was the general manager of CEFOC-AUSTAR Pharmaceutical Engineering (Shanghai) Co., Ltd.; from October 2010 to February 2013, he served as the deputy general manager of China Electronics System Engineering No.4 Construction Co., Ltd.; from February 2013 to February 2019, he was the vice president of China Electronics System Engineering No.4 Construction Co., Ltd., and concurrently served as a director of Fusi Tehuile (Hebei) Engineering Design Co., Ltd. from June 2015 to February 2019; from February 2019 to December 2019, he was the chief expert of China Electronics System Engineering No.4 Construction Co., Ltd., the chairman of PHARMAC Systematic Engineering (Shanghai) Co., Ltd., and the director of Fusi Tehuile (Hebei) Engineering Design Co., Ltd.